ARPA-H PROSPR in 2026: Seven Awards, $144M, and What Has Not Been Proven Yet
ARPA-H's PROSPR program funds seven teams with up to $144 million. Here is what the program is testing, what its milestones mean, and why it is not yet validation of a healthspan treatment.
Review note, August 28, 2026: We replaced speculative claims about FDA acceptance, insurance coverage and validation of clinic prescribing with the current ARPA-H program record. PROSPR is active research, not evidence that any tested intervention extends human healthspan.
ARPA-H’s PROactive Solutions for Prolonging Resilience program, or PROSPR, has selected seven teams for contracts worth up to $144 million over five years. The funding is contingent on teams meeting aggressive milestones.
The program matters because it is trying to make healthspan studies faster and more measurable. It does not establish an approved definition of healthspan, validate a surrogate endpoint or prove that a drug slows aging.
What ARPA-H has actually funded
ARPA-H announced the seven teams on February 24, 2026. Its stated program goals include:
- identifying early molecular and physiological changes associated with declining resilience;
- developing measurements that could support shorter healthspan trials;
- using decentralized and in-home tools to reduce trial burden;
- testing candidate interventions over roughly one to three years rather than waiting decades for mortality outcomes.
These are research objectives. Contract ceilings are not the same as money already spent, and program selection is not a positive clinical result.
Three projects with direct clinical relevance
| Team | Confirmed work | What remains unknown |
|---|---|---|
| Stanford University | Develop the PROSPR-IC intrinsic-capacity score and evaluate it during a one-year lifestyle intervention | Whether the score reliably predicts patient-important outcomes across populations |
| UT Health San Antonio | Conduct a phase 3 hybrid trial involving an SGLT2 inhibitor, rapamycin and semaglutide | Whether any intervention improves the prespecified healthspan measures and whether benefits outweigh harms |
| Columbia University | Analyze prior trials to identify intervention-responsive biomarkers | Whether a candidate biomarker can be validated for future clinical or regulatory use |
Other selected teams, including Apollo Alpha, Cambrian, Linnaeus and a University of Rochester-led consortium, address additional interventions, trial tools and early physiological changes. Their inclusion should not be read as endorsement of a product or protocol.
The May 2026 framework is a proposal, not an endpoint approval
The current PROSPR program page lists a May 2026 consensus framework on intrinsic capacity. ARPA-H describes it as recommendations to the FDA plus a stepwise validation plan toward possible future use in geroscience and healthspan trials.
That wording is important. A recommended validation path is not the same as a regulator accepting a biomarker as a surrogate endpoint. As of this review, the program page does not report completed treatment outcomes from the funded trials.
What PROSPR does not validate for longevity clinics
The involvement of rapamycin, semaglutide or an SGLT2 inhibitor does not validate an existing clinic’s off-label protocol. A rigorous trial can support, weaken or narrow a hypothesis. Until results are available, a clinic should not present federal study as proof that its dose, patient selection or monitoring plan works.
PROSPR also does not currently provide:
- an FDA-approved treatment for aging;
- a universal biological-age test for clinical decisions;
- evidence that insurers will cover longevity programs;
- a standard panel that every clinic should sell;
- permission to substitute a commercial test for established clinical endpoints.
Patients considering these medications should evaluate the approved indication, individual risk and clinician monitoring separately from the longevity hypothesis. Our evidence-versus-experimentation guide provides a practical framework.
What would count as meaningful progress
For PROSPR to change clinical practice, the field will need more than a promising score. Useful evidence would include:
- prespecified outcomes and public trial registrations;
- reproducible measurements across sites and populations;
- a clear relationship between biomarker change and function, disease or quality of life;
- adverse-event and discontinuation data;
- peer-reviewed results with enough detail for independent assessment;
- regulatory decisions that state exactly how a measure may be used.
Bottom line
PROSPR is a significant public investment in the tools needed to test healthspan hypotheses. Its seven awards and $144 million ceiling show institutional commitment to the problem. They do not yet show that a treatment extends healthy human life. The responsible interpretation in 2026 is to follow the milestones and results, not convert the funding announcement into a clinical verdict.